论文部分内容阅读
目的:研究干扰素压缩雾化吸入治疗小儿呼吸道病毒感染性疾病的临床疗效和安全性。方法:按入院顺序,将200例呼吸道病毒感染性疾病患儿,随机分为实验组和对照组各100例;对照组仅常规进行对症治疗,实验组在常规对症治疗的同时,配合干扰素加压雾化吸入治疗5天评价2组疗效,进行统计学分析。结果:实验组的治愈率和未愈率分别为76%和1%,对照组的治愈率和未愈率分别为40%和2%,2组间疗效差异有显著性,P<0.05。结论:干扰素压缩雾化吸入可显著提高小儿呼吸道病毒感染性疾病疗效,且使用安全,无毒副作用。
Objective: To study the clinical efficacy and safety of interferon-compressed atomization inhalation in the treatment of pediatric respiratory virus infectious diseases. Methods: According to the order of admission, 200 children with respiratory virus infectious diseases were randomly divided into experimental group and control group with 100 cases in each group. The control group was treated with symptomatic treatment only routinely. The experimental group was treated with interferon plus Pressure aerosol inhalation treatment for 5 days to evaluate the efficacy of two groups for statistical analysis. Results: The cure rate and the unharmed rate in the experimental group were 76% and 1%, respectively. The cure rate and the unharmed rate in the control group were 40% and 2%, respectively. The difference between the two groups was significant (P <0.05). Conclusion: Compressed inhalation of interferon can significantly improve the therapeutic effect of respiratory virus infection in children, and safe, non-toxic side effects.